The purpose of this IAA is to obtain diagnostic services from Pacific Northwest National Laboratory (PNNL), Department of Energy (DOE) to support the Early Detection Research Network?s (EDRN) efforts to prioritize, verify and validate candidate biomarkers for cancer early detection, diagnosis and early prognosis. The laboratory, herein Biomarkers Reference and Resource Laboratory (BRCC), will serve as a diagnostic core and will measure the candidate biomarkers in specimens provided by the EDRN using antibody free quantitative assays such as Liquid Chromatography - Selected Reaction Monitoring Mass Spectrometry (LC-SRM-MS) and Parallel Reaction Monitoring Mass Spectrometry PRM-MS. The initial work will focus on measuring EDRN candidate biomarkers in prostate cancer specimens (tissue, plasma, serum and urine). However, the measurements will be later extended to include additional candidate biomarkers for cancers supported by the EDRN including cancers of the bladder, pancreas, liver, colon, lung, breast and ovaries. Currently, the limit of detection of a serum or plasma or urine biomarker, using high-pressure high-resolution separation coupled with intelligent selection and multiplexing (PRISM) LC-SRM-MS, is ~50 pg/mL and limit of detection of a tissue biomarker is ~2 amol/g of tumor tissue.
